The European Medicines Agency (EMA) has three mission-critical task forces which support its human and veterinary medicines divisions, bringing together expertise to drive transformational change in high-priority areas of the Agency's work.
The Digital Business Transformation task force drives complex, digital change initiatives that impact on EMA's strategy, operational structure and operations in relation to the European medicines regulatory network, its partners and stakeholders. This includes adapting EMA operations to fundamental changes brought by legislative initiatives, digital technologies and global trends to meet stakeholders’ needs and expectations.
The Data Analytics and Methods task force builds up capability and capacity within EMA and across the European medicines regulatory network to deliver robust clinical evidence for benefit-risk decision-making on medicines. This is achieved through:
- supporting a strategy to transform clinical trials in Europe;
- providing expert scientific advice on products under development;
- strengthening support for marketing authorisation assessments;
- providing expert methods advice and data analysis for products on the market.
The Regulatory Science and Innovation task force enables the continuous ‘future-proofing’ of the Agency and the European medicines regulatory network. This is done by addressing key scientific and technological trends and their translation through the development of EMA’s regulatory science strategy, planning and governance. It seeks to offer an enhanced first point of contact service to developers, in particular small and medium-sized enterprises (SMEs) and academia.
The task forces remain flexible to adapt as required by the Agency.